Help Cure Duchenne Now, Donate Today

Help CureDuchenne Now!

With only 5 days left in the year, CureDuchenne is doing all it can to raise the dollars needed to fund promising and innovative research to find a cure for Duchenne muscular dystrophy. We have a successful track record of translating promising research into clinical trials, and have funded seven research projects that have gone into human clinical trials.

We recently launched CureDuchenne Ventures to help us identify and fund a robust pipeline of prospective therapies to treat all aspects of the disease and find a cure for Duchenne.  CureDuchenne Ventures provides the opportunity for venture philanthropists, foundations, donors and investors to join forces to invest in the most promising research. Our first project is with Lexicon Pharmaceuticals, whose Phase 2 development drug has shown the potential in preclinical studies to help regenerate muscle in the mdx mouse model of Duchenne. If successful in the clinic, this drug has the potential to benefit all boys with Duchenne, regardless of their genetic mutation, and it is our goal to initiate a proof of concept study in Duchenne patients in 2014.   

The Phase 1 clinical study will cost approximately $800,000, and we need to raise at least $150,000 by the end of 2013 so we don’t delay the program. Your donation will leverage additional funding to find a cure for Duchenne.

If you have donated to our year end campaign, we thank you.  Thank you for giving hope to the 300,000 boys worldwide with Duchenne.

If you haven’t donated yet we could still use your support.  We believe that if we act aggressively now, our boys won’t need this help in the future. Go to

We wish you and your family a happy and healthy new year.



Debra Miller, Founder and CEO, CureDuchenne

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.